Teva in Q1: who captures the value if the externally funded pipeline works
Teva is using partner funding to advance expensive assets such as duvakitug, DARI and TEV-408 without carrying the full R&D burden in the current quarter. That lowers expense now, but if the drugs work, milestones, royalties and profit-sharing will determine how much upside remains with shareholders.
Lower expense today, layered claims tomorrow
The main first-quarter article argued that Teva is no longer only a financial-survival story. Innovative medicines are growing, the pipeline is advancing and profitability is improving. This continuation isolates the question the quarter opened but did not fully unpack: how much of the pipeline's future value will actually remain with shareholders as more assets are developed with partner capital.
That question matters precisely because the near-term numbers look helpful. Net R&D expenses declined to $222 million in the first quarter, down 10% from $247 million in the prior-year quarter. But those expenses are reported net of partner contributions, and in the same quarter Teva recognized $30 million of R&D reimbursement from Blackstone around duvakitug and another $30 million from Abingworth around DARI. The lower expense is not only efficiency. Part of it is a conversion of current R&D spending into future partner claims if the products succeed.
That is not necessarily negative. For a pharmaceutical company with high debt, a continuing legal tail and a cash-funded Emalex acquisition, sharing development risk is a rational tool. It allows several programs to move forward in parallel without turning every large clinical trial into a full cash burden for the company. Still, it is not free money. When the asset works, the partner does not disappear: it receives a milestone, royalties, success payments or a share of profit.
The chart shows funding caps, not guaranteed revenue. TEV-408 includes $75 million based on Phase 1b results in vitiligo and an option for another $425 million subject to future Phase 2b results. DARI reflects the original $150 million from Abingworth plus a $50 million increase signed in January 2026. For olanzapine LAI, Royalty Pharma has already provided $100 million that was recorded as R&D reimbursements in 2023 and 2024. That is the reference point: Teva's pipeline is broader, but it also carries more third-party economic rights.
| Asset | Stage and framework | What lowers the current burden | What may reduce future value |
|---|---|---|---|
| duvakitug | Phase 3 in Crohn's disease and ulcerative colitis, in collaboration with Sanofi | Blackstone will provide up to $400 million over four years, with $30 million recognized as reimbursement in Q1 | A milestone approximately equal to the funding amount, commercial milestones and royalties, on top of the Sanofi economics |
| DARI | Phase 3 in asthma | Abingworth increased funding from $150 million to $200 million, with $30 million recognized as reimbursement in Q1 | A milestone equal to the amount funded and sales-based success payments |
| TEV-408 | Anti-IL-15 in vitiligo and Celiac disease, before Phase 2b in vitiligo | Royalty Pharma may provide up to $500 million, including $75 million in the first component | A milestone of up to 130% of the funded amount under certain conditions, plus royalties if commercialized |
| olanzapine LAI | Submitted to the FDA in December 2025 and accepted for review in February 2026 | Royalty Pharma has already provided $100 million for development | A milestone equal to the funded amount, paid over 5 years, plus royalties after commercialization |
Duvakitug no longer has simple economics
Duvakitug is the sharpest example because two different economic layers sit on the same asset. The first layer is Sanofi. In October 2023, Teva entered into an exclusive collaboration with Sanofi to co-develop and co-commercialize duvakitug, an anti-TL1A medicine for Crohn's disease and ulcerative colitis. The company received a $500 million upfront payment in the fourth quarter of 2023. In October 2025, after Phase 3 studies began in both indications, it received two $250 million development milestones, or $500 million in total, which were recognized as revenue.
The positive side is clear: even before commercialization, duvakitug has already generated meaningful milestone revenue for Teva. There is also potential for up to another $500 million in development and launch milestones. But the future economics do not belong to the company alone. Sanofi leads the Phase 3 program, the two companies equally share remaining global development costs and profits and losses in major markets, and other markets are subject to a royalty arrangement. Teva will lead commercialization in Europe, Israel and specified other countries. Sanofi will lead commercialization in North America, Japan, other parts of Asia and the rest of the world.
The second layer is Blackstone. In March 2026, Teva signed a funding agreement under which Blackstone will provide up to $400 million over four years to support duvakitug development. If the product receives regulatory approval, the company will pay Blackstone a milestone approximately equal to the total funding provided, plus commercial milestones and royalties upon commercialization. The first quarter already included $30 million of R&D expense reimbursement.
That creates a different risk profile. If duvakitug fails, Teva's direct spending burden is lower than it would have been without partners, but no commercial asset is created. If it succeeds, the company benefits from an advanced asset, further milestones and commercialization in the geographies it leads, but shareholders receive the residual economics after Sanofi, Blackstone and royalty mechanisms. Clinical success can still be a major event. It is just not equivalent to 100% economic ownership of a successful medicine.
DARI and TEV-408 show two versions of the same tradeoff
DARI is a structure in which Teva keeps more commercial control while giving partners a meaningful role in execution and future economics. Launch Therapeutics leads the operational execution and management of the planned clinical trials. Teva retains primary responsibility for manufacturing, U.S. regulatory interactions and commercialization. For a company trying to expand its pipeline without loading all trial costs onto the balance sheet, that is an efficient structure.
But success has a price here too. Abingworth provided $150 million to fund ongoing DARI development, and in January 2026 the agreement was increased by another $50 million. Teva recognized R&D reimbursements of $42 million in 2024, $98 million in 2025 and $30 million in the first quarter of 2026. In exchange, if the product advances to regulatory and commercial success, the company will pay a milestone equal to the amount actually funded, as well as success payments based on DARI sales.
TEV-408 is different. Royalty Pharma's funding framework still has two stages. The first $75 million is based on Phase 1b results in vitiligo, while the additional $425 million is an option Royalty Pharma may exercise based on future Phase 2b results in vitiligo. That Phase 2b trial is expected to begin in the second half of 2026. So the full $500 million should not be read as cash already in hand. It is mainly a signal that a relatively earlier-stage asset can attract external financing if the next data point remains strong.
If TEV-408 advances, Royalty Pharma's future claim is also meaningful. Teva will pay a milestone in the amount actually funded, which could reach up to 130% under certain conditions, plus royalties after commercialization. The checkpoint is therefore not only whether funding arrives. It is what type of funding arrives, at which stage, and what it buys the partner on the other side.
Olanzapine LAI, the most advanced asset among these examples, shows that the model is not limited to early programs. The NDA was submitted to the FDA in December 2025 and accepted for review in February 2026. Royalty Pharma has already provided $100 million to fund development, and Teva will pay a milestone equal to the funded amount over 5 years, plus royalties after commercialization. Even when the company leads global development and commercialization, an external claim has to be included in the economics.
Who captures the value if the products work
Externally funded pipeline assets create three types of value, and they do not all land in the same place. The first is accounting and near-term cash value: R&D reimbursements reduce net expense and preserve cash. The second is strategic value: the company can advance more programs in parallel, especially in immunology, neuroscience and biosimilars, without choosing too early among assets. The third is commercial value if the drug works. That is where the real split begins.
| Value layer | First beneficiary | What shareholders need to test |
|---|---|---|
| Quarterly R&D reimbursements | The company, through lower net expense | Whether lower R&D reflects efficiency or funding that creates future partner rights |
| Lower development risk | The company and partners together | Whether the agreement accelerates an asset that would otherwise move more slowly, or just swaps cash today for more expensive cash tomorrow |
| Successful commercialization | The company, the commercial partner and the funder | The profit share or royalty burden left after milestones, royalties and success payments |
| Market valuation of the pipeline | Shareholders, if the market gives early credit | Whether the market is pricing gross sales of a successful drug or the residual economics after partners |
The practical point is that Teva is not building a weak pipeline. On the contrary, the willingness of Blackstone, Abingworth, Royalty Pharma and Sanofi to fund or partner around core assets is a quality signal. These counterparties are not entering agreements just to replace operating expense. They take part of the risk, and in return they receive a claim on part of the result.
That means three sentences that sound similar have very different economics. "The asset advanced clinically" is a scientific statement. "The company received funding" is a cash-flow statement. "Shareholders will capture most of the upside" is an economic statement that still has to be proven asset by asset. In duvakitug, for example, there is profit and loss sharing with Sanofi in major markets and a payment layer to Blackstone. In DARI, there are success payments. In TEV-408, there may be a milestone of up to 130% of the funded amount and royalties. These are not minor legal details. They are the routes through which upside is divided.
The next few quarters will test the residual economics
The first check is whether net R&D expenses continue to decline or stabilize, and whether that decline is accompanied by real clinical progress. Lower expense without progress is not an improvement. Clinical progress with R&D reimbursements can be an improvement, but only if the company's retained economics still justify the investment.
The second check is TEV-408. The second half of 2026 is expected to bring the start of Phase 2b in vitiligo. If the data leads Royalty Pharma to exercise the additional funding option, that would be a stronger external validation of the asset, but it would also increase the funder's future claim. The market may treat that as positive news, and reasonably so. The next question should be what remains for Teva after the funding, milestone and royalties.
The third check is duvakitug. The Phase 3 start in October 2025 already brought Teva $500 million of Sanofi milestones. From here, additional value will depend on the program advancing without material delays and without costs, royalties and partner sharing absorbing too much of the future contribution. Any update on trial recruitment, development costs or regulatory timelines will affect the market's interpretation of the asset.
The fourth check is olanzapine LAI and DARI. The first is already in regulatory review, and the second is in Phase 3. In both cases, the question should move from "is there an asset" to "how much does it cost to reach the market, and how much remains after partners." That is where the quality of Teva's transition will be measured: not only how much pipeline exists, but how much of that pipeline can become recurring cash accessible to shareholders.
The right closing line is not that partnerships damage the story. They probably make it possible. Without partners, some programs would require more cash, more risk and more patience from the balance sheet. But as the pipeline becomes more central to the company's valuation, it has to be read net of the rights granted along the way. The next bottleneck is not only a successful trial. It is proof that a successful drug, if it arrives, leaves enough economics with Teva after every partner receives its share.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.